针对TROP2的CAR T细胞疗法的系统工程克服了固体瘤中的抵抗路径
Elliott J Brea1, Simon Baldacci1, Neil Savage1
1Dana-Farber Cancer Institute, Boston, Massachusetts.
Cancer immunology research
|September 8, 2025
概括
针对TROP2的化学抗原受体 (CAR) T细胞为固体瘤提供了抗体-药物结合物的有效替代品. 这些CAR T细胞的理性工程克服了耐药性,提高了耐用性,并为未来的癌症疗法提供了一个平台.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 基于抗体的癌症疗法面临着诸如抗原下调和耐药性等局限性.
- 针对TROP2的抗体-药物联合体 (ADC) 显示出有效性,但在固体瘤中缺乏持久的反应.
研究的目的:
- 开发针对TROP2的化学抗原受体 (CAR) T细胞,作为ADCs的持久替代品.
- 设计CAR T细胞以克服当前疗法观察到的抗性机制.
主要方法:
- 开发针对TROP2的CAR T细胞.
- 对固体瘤模型进行CAR T细胞功效测试,包括对ADCs耐药的模型.
- 通过使用全人类单域结合剂来增强定位和克服阻力,设计双重类型的CAR.
主要成果:
- 针对TROP2导向的CAR-T细胞对各种固体瘤模型表现出高强度.
- 在抗体-药物合物耐药的模型中,CAR T细胞疗法保持了强度.
- 设计的双类CARs成功地预防了细胞治疗耐药性.
结论:
- 向TROP2的CAR-T细胞代表了对TROP2+固体瘤的强大且可能更持久的免疫疗法.
- 汽车的理性工程,特别是双型设计,可以克服阻力路径.
- 这种CAR工程方法为开发下一代癌细胞疗法提供了一个平台.
相关概念视频
01:27Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K